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1. Introduction1
Pulmonary Arterial Hypertension (PAH) refers to a kind 
of pathophysiology syndrome where weakened of vascular 
caused by any system or local lesion which make the whole 
pulmonary pressure increased, eventually leads to right 
heart failure. This study aims to discuss about the right 
arterial hypertenion leads to heart failure as the research 
object and to explore the diagnosis and treatment of right 
heart failure. 
2. Materials and method
2.1. General information
A total of 60 patients with right heart failure were ran-
domly choose including male 40 cases, female 20 cases, 
aged 55‒70 years old, with an average age of 60.5 years. All 
the subjects were choose in accordance with the standards 
which are consistent with 2008 Haddad of right heart fail-
ure clinical staging criteria 2: (1) Period with right heart 
failure risk factors have no heart failure symptoms; (2) 
period with right ventricular dysfunction or organic heart 
disease no heart failure symptoms; (3) Period with right 
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ventricular dysfunction or structural heart disease; (4) 
Period refractory right heart failure. All patients were ran-
domly divided into observation group and control group 
where 30 cases of each group, two groups of gender, age 
and course of the disease. The clinical data comparison dif-
ference show that there has no statistical significance (p > 
0.05), have comparability.
2.2. Treatment
In control group 30 cases of patients were applied with 
loop diuretic torasemide for first dose of 20 mg through 
intravenous injection and after 2−4 hours later dose is re-
duced to half; 0.4 mg of Cardiac glycosides deacetylation 
lanatoside was injected via intravenous injection, with ev-
ery 2−4 hours later give 0.2−0.4 mg and total was 1−1.6 
mg; Based on the ventricular rate adjust the dosage, after 
patients with clinical symptoms stabled and fluid retention 
marked improved, switch to digitalis preparations (start 
with small doses, until the maximum tolerated dose). 
On the other hand, observe group on the basis of con-
trol group were used positive inotropic drug dobutamine 
200 mg of 50 ml dubbed into micro pump, started with 
small dose 1-5 ug/kg/min by center vein pipe pump, and 
increase the dosage until until reach 8−12 ug/kg/min. Pa-
tients with severe hypotension patients can be associated 
with dopamine or milrinone.
2.3. Curative effect judgment standard
Marked clinical criteria: improvement of cardiac class II 
or above; (1) Effective: Heart function improved class I or 
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(2) Invalid: heart function improved less than class I, signs 
and symptoms not improved, even become worse.
2.4. Statistical method
Two groups were compared by t test and the total effi-
ciency was expressed in percentage (%) of each group and 
the number of cases was compared by r test. The following 
table is as Table 1.
All the data were analyzed by SPSS 15.0 statistical software 
when p < 0.05, the difference was statistically significant.
3. Result
In the observation group of 30 cases, 14 cases produce an 
effect, 15 cases is effective, and 2 cases is invalid where 
the total effective rate is 96.6%. In the control group of 30 
cases, 8 cases produce an effect, 17 cases is effective and 5 
cases is invalid, the total effective rate is 83.3%. Two group 
total effective rate and confinement (day) have significant 
difference (p < 0.05). 
Two groups of patients all have no adverse events oc-
curred during the use of medication. There is no abnormal 
in blood, urine, stool routine and liver and kidney function 
during the period of medication. Thus, we can see safety of 
the drug is good and does not appear obvious side effects.
4. Discussion
Pulmonary arterial hypertension is pulmonary vascular 
bed exhausted caused by a variety of causes, make progres-
sive pulmonary resistance increases, eventually leads to 
right heart failure pathophysiology syndrome. Pulmonary 
arterial hypertension is the main reason of right heart fail-
ure, and right heart failure is the only way to cause all types 
of pulmonary hypertension patient disability and death. 
Not only that, it is the most important factors of pulmo-
nary arterial hypertension patient prognosis. At present, 
local and international guidelines will reflect the right pa-
rameters are indicators of cardiac function in patients with 
pulmonary hypertension as important risk stratification. 
However, a related function of right ventricle is still a rela-
tively new field. Therefore, the US National Heart, Lung 
and Blood Institute will be listed as the focus of future 
research direction in the field of cardiovascular. In recent 
years, pulmonary arterial hypertension induced right heart 
failure gradually be taken seriously, there is likely to be-
come one of the hotspot in research of heart failure in the 
future [1].
Pulmonary arterial hypertension induced right heart 
failure has been a research focus in recent years. The early 
pulmonary arterial hypertension can lead to the right ven-
tricle compensatory reconstruction, but still can maintain 
normal cardiac output and against the increase of pul-
monary vascular resistance against the formation of right 
ventricular hypertrophy. As the progress of the disease, the 
right ventricle hypertrophy insufficient against pressure 
load change beyond the scope of myocardial compensa-
tory, thus decompensated ventricular reconstruction, that 
is the right heart failure. In the pulmonary arterial hyper-
tension induced by chronic right heart failure model, heart 
chamber become plump due to compensatory, then hap-
pen the right heart failure, pulmonary arterial hyperten-
sion induced disease throughout the right heart. Research 
shows that when pulmonary hypertension patients in right 
ventricular filling the biggest, the right ventricle through a 
ventricular septal to left ventricle there is a pressure gradi-
ent. This is because the right ventricular pressure overload 
lead to right ventricular free wall contraction prolonged. 
However, as left ventricle has entered the early diastolic, 
right ventricular pressure has more than the left ventricle, 
leads to the formation of a cross between pressure gradi-
ent, and appear ventricular septal reverse movement. This 
not only affect the right ventricular end systolic contrac-
tion, also reduces the early left ventricular diastolic filling, 
make left ventricular end-diastolic volume reduced and 
directly affects the left ventricular cardiac output, in turn 
lead to pulmonary pressure rise further. This will promote 
the occurred and development of right heart failure. Pul-
monary arterial hypertension leads to right heart failure 
has many other factors, such as: ventricular remodeling, 
neural endocrine hormone, cytokine activation, myocar-
dial cell apoptosis, inflammation, oxidative stress and ab-
normal gene expression, etc, they through the pulmonary 
hypertension, and lead to right heart failure occurred dur-
ing the process of development. 
General treatments of right heart failure include con-
trol fluid retention, limiting sodium intake (≤2 g/d), body 
weight monitoring, careful application of diuretics. Clas-
sification of physical activity in patients with right heart 
failure and pulmonary hypertension may be beneficial. 
Recent studies have shown that patients with chronic se-
vere pulmonary hypertension have moderate intensity 
exercise can significantly improve the sport ability and life 
quality. There are many clinical trials have confirmed that 
β-receptor blockers can improve the symptoms of heart 
failure and the cardiac function and thus reduce death. 
Angiotensin II converting angiotensin enzyme inhibitor 
(ACEI) and angiotensin II receptor blocker (ARB) which 
can lower blood pressure and cardiac afterload thus reduce 
the thickness and stiffness of the arterial wall, weak angio-
Table 1. Comparison of two groups after treatment effect, confinement (day) and total effective rate (%).
Group n Produce an effect Effective Invalid Confinement (day) Total effective rate (%)
Observe group 30 14 15 1 7 ± 3 96.6
Control group 30 8 17 5 10 ± 4 83.3
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tensin II will effect on the contraction of coronary artery 
thus  improve cardiac function. Since most of right heart 
failure is associated with pulmonary hypertension, in view 
of the targeted drug therapy pulmonary hypertension can 
progress soon, mainly include calcium channel blockers, 
prostacyclin and its structural analogs, endothelin receptor 
antagonist, phosphodiesterase type 5 inhibitors and Rho 
kinase inhibitors. China scholars have confirmed, sildena-
fil can safely and effectively treat pulmonary hypertension, 
and recommended to use sildenafil 25 mg, 3 times a day. In 
addition, Rho kinase inhibitors may be a promising selec-
tive pulmonary artery vasodilators, but still need further 
clinical trials [2].
The right ventricle structure anatomical and functional 
features have great differences with left ventricular where 
right ventricular myocardial fibers are arranged in series, 
compared with the left ventricle. The characteristics of the 
right ventricle are wall thin, low pressure, small volume 
and surface area ratio is small, so it have good compliance. 
Therefore if the right ventricle load is increased the heart 
chamber will eventually expand to accommodate the in-
creased of pulmonary artery pressure. The pathogenesis of 
right heart failure is very complicated and maybe include 
myocardial injury and stress, sympathetic nervous system 
(SNS), renin-angiotensin aldosterone system (RAAS), ac-
tivation of endothelin (ET) and so on ventricular remod-
eling, etc. Heart failure also activate neurotrophic factor 
like: vasopressin, prostaglandins, atrial peptide, brain na-
triuretic peptide, tumor necrosis factor, interleukin-1, in-
terleukin-6 and other neurological factors. These neuroen-
docrine factor activation levels and severity of heart failure 
were positively correlated. Neuroendocrine system activa-
tion can be directly toxic to the heart and activate vascu-
lar endothelial directly, make myocardial cell thickening, 
apoptosis and necrosis, increase myocardial fibrosis and 
make heart expending and reshaping. Heart reshaping lead 
to heart structure and functional change is the mechanism 
of heart failure where the excessive activation of neuroen-
docrine system plays a very important part in heart re-
shaping. Pulmonary arterial hypertension is the important 
determinants in right heart function for failure develop-
ment process. In the process of the development of PAH, 
molecular and genetic levels factors exist in smooth muscle 
endothelial cells and vascular adventitia, also exist con-
striction of blood vessels and vasodilation environmental 
imbalances, those all are pulmonary hypertension research 
directions. Pulmonary hypertension and right heart failure 
play an important role, in order to overcome the resistance 
of pulmonary hypertension and right ventricular hypertro-
phy [3]. When early pulmonary hypertension occur, right 
ventricular still capable for compensation, however when 
late pulmonary artery pressure continues to rise, more 
compensatory ability is required for the right ventricle. 
This will lead to right heart failure where decreased cardiac 
output, right ventricular end-systolic residual blood vol-
ume increased as well as end-diastolic pressure increased. 
Right heart failure includes pressure overload, volume 
overload, myocardial ischemia, myocardial disease and 
pericardial diseases. Based on anatomy of right and left 
ventricles, different features of right heart failure treatment 
cannot be equated in left heart failure treatment. After the 
1990s, gradually clear cardiac remodeling is a fundamental 
mechanism for the development of heart failure and neural 
endocrine suppression blocking cardiac remodeling. Fail-
ure to repair the biological properties of cardiomyocytes is 
a milestone in the history of the treatment of heart failure. 
Right heart failure in patients with acute hemodynamic 
disorders often uses inotropic drugs as a treatment. This 
study was a joint group of inotropic dobutamine, to adjust 
cardiac function through controlled observation and the 
application in patients with heart failure remission after 
amine level, the total effective rate, there was a significant 
difference in hospitalization date with the control group. 
Therefore, dobutamine is able to improve cardiac index, 
increase cardiac output, reduce pulmonary arterial resis-
tance and relieve symptoms of heart failure, reduced mor-
tality and improve the prognosis of patients. After all, this 
treatment is worthy for clinical application
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